ArticleTheranostics2020
LDH-stabilized ultrasmall iron oxide nanoparticles as a platform for hyaluronidase-promoted MR imaging and chemotherapy of tumors.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Toward multifunctional nanoplatforms based on layered double hydroxides (LDHs) for cancer therapy: From structural design to application.Bioactive materials · 2026Review
- Advancements in Iron Oxide Nanoparticles for Multimodal Imaging and Tumor Theranostics.Current medicinal chemistry · 2025Review
- Nanotheranostics: A Cutting-edge Technology for Cancer Management.Current pharmaceutical biotechnology · 2025Review
- Hyaluronic Acid Modified Metal Nanoparticles and Their Derived Substituents for Cancer Therapy: A Review.Pharmaceutics · 2023Review
- Multifunctional Layered Double Hydroxides for Drug Delivery and Imaging.Nanomaterials (Basel, Switzerland) · 2023Review
- Two-dimensional-TiFrontiers in bioengineering and biotechnology · 2023Article
- Nanomagnet-facilitated pharmaco-compatibility for cancer diagnostics: Underlying risks and the emergence of ultrasmall nanomagnets.Journal of pharmaceutical analysis · 2022Review
- Magnetite Nanoparticles in Magnetic Hyperthermia and Cancer Therapies: Challenges and Perspectives.Nanomaterials (Basel, Switzerland) · 2022Review
- Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics.Pharmaceutics · 2022Review
- Design of Magnetic Nanoplatforms for Cancer Theranostics.Biosensors · 2022Review
- pH-responsive hybrid platelet membrane-coated nanobomb with deep tumor penetration ability and enhanced cancer thermal/chemodynamic therapy.Theranostics · 2022Article
- Hyaluronic Acid-Stabilized FeFrontiers in pharmacology · 2022Article
- Magnetic nanoparticles in theranostics of malignant melanoma.EJNMMI research · 2021Review
- Trifunctional Graphene Quantum Dot@LDH Integrated Nanoprobes for Visualization Therapy of Gastric Cancer.Advanced healthcare materials · 2021Article
- Polydopamine-Coated Laponite Nanoplatforms for Photoacoustic Imaging-Guided Chemo-Phototherapy of Breast Cancer.Nanomaterials (Basel, Switzerland) · 2021Article
- Recent Advances in Immunosafety and Nanoinformatics of Two-Dimensional Materials Applied to Nano-imaging.Frontiers in immunology · 2021Review
- Progress of Cancer Nanotechnology as Diagnostics, Therapeutics, and Theranostics Nanomedicine: Preclinical Promise and Translational Challenges.Pharmaceutics · 2020Review
- A brain glioma gene delivery strategy by angiopep-2 and TAT-modified magnetic lipid-polymer hybrid nanoparticles.RSC advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of unique theranostic nanoplatforms for tumor imaging and therapy remains an active topic in current nanomedicine. Here, we designed a novel targeted theranostic nanoplatform for enhanced
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.